DRG Epidemiology's coverage of acute ischemic stroke (AIS) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report both the incidence and prevalence of AIS for each country, as well as annualized case counts projected to the national population.
DRG Epidemiology's AIS forecast will answer the following questions:
How will changes in the levels of exposure to known risk or protective factors affect the number of events of AIS per year?
Of all AIS events, how many in each country across the major mature pharmaceutical markets have been formally diagnosed?
Of all AIS events, how many in each country across the developed world are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of AIS over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology also provides at least ten years of forecast data for the following AIS subpopulations:
Total Event Estimates of Ischemic Stroke per 1,000 People of All Ages in 2021
Relative Sizes of the Factors Contributing to the Trend in Total Events of Ischemic Stroke Over the Next 10 Years
Analysis of Diagnosed Events of Ischemic Stroke in the Countries Under Study in 2021 by Time Between Stroke Onset and Presentation to a Hospitalttttttttt
Analysis of the Total Events of Ischemic Stroke in 2021 by Diagnosed and Drug-Treated Statusttttttttt
Number of Total Events of Ischemic Stroke Avoided Over 2021-2031 in the Countries Under Study due to Trends in Riskttttttttt
Total Lifetime Prevalent Cases
Diagnosed 12-Month Prevalent Cases
Time Between Stroke Onset and Presentation to a Hospital
Diagnosed Events of Ischemic Stroke
Diagnosed Drug-Treated Events of Ischemic Stroke
Studies Included in the Analysis of Ischemic Stroke
Studies Excluded From the Analysis of Ischemic Stroke
Risk / Protective Factors
Risk / Protective Factors for Ischemic Stroke
Narendra Parihar, M.P.H., is a principal epidemiologist at Clarivate. His areas of interest are cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer. A former dentist, he earned his M.P.H. from the Tata Institute of Social Sciences in Mumbai.
Sunali Goonesekera, S.M., is a senior epidemiologist at Clarivate. Previously, Ms. Goonesekera conducted epidemiological research on racial/ethnic disparities in metabolic diseases at the New England Research Institute and lead-authored two manuscripts. She has contributed to multiple publications in peer-reviewed journals in epidemiology and the biological sciences. She holds a master’s degree in epidemiology from the Harvard School of Public Health and a B.A. in biology (Honors) from Dartmouth College.